![]() | |
Clinical data | |
---|---|
Trade names | Carafate |
AHFS/Drugs.com | Monograph |
MedlinePlus | a681049 |
License data |
|
Routes of administration | By mouth, rectal |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 3-5% (local acting) |
Metabolism | GI; liver: unknown |
Elimination half-life | unknown |
Excretion | Feces, urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.053.636 |
Chemical and physical data | |
Formula | C12H54Al16O75S8 |
Molar mass | 2086.67 g·mol−1 |
![]() ![]() |
Sucralfate, sold under various brand names, is a medication used to treat stomach ulcers, gastroesophageal reflux disease (GERD), radiation proctitis, and stomach inflammation and to prevent stress ulcers.[3][4][5] Its usefulness in people infected by H. pylori is limited.[3] It is used by mouth (for upper GIT ulcers) and rectally (for radiation proctitis).[3][5]
Common side effects include constipation.[3] Serious side effects may include bezoar formation and encephalopathy.[6] Use appears to be safe in pregnancy and breastfeeding.[6] How it works is unclear but is believed to involve binding to the ulcer and protecting it from further damage.[3][6]
Sucralfate was approved for medical use in the United States in 1981.[3] It is available as a generic medication.[6][7] In 2021, it was the 186th most commonly prescribed medication in the United States, with more than 2 million prescriptions.[8][9]
Carafate FDA label
was invoked but never defined (see the help page).© MMXXIII Rich X Search. We shall prevail. All rights reserved. Rich X Search